MAHA Research Priorities: Towards a Rational Protocol for Measles Treatment

Many physicians have taken to social media to express concern over measles infections. We do not have sufficient research on treatments. A review of 16000 papers that mention measles and tx informs.

To the Reader: This is not an active research program proposal, but it should be, given the thousands of expressions of concern over measles. This is not medical advice; consult with your physician or pediatrician. This is printable and can be shared with your doctors. A full research program could be established to study therapies and treatments for all vaccine-targeted pathogens to help Make America Healthy Again.

Measles remains one of the most contagious viral diseases. While serious cases are extremely rare in the US, the virus is capable of causing severe complications and death, particularly in malnourished and immunocompromised individuals. Measles has a natural 3-year cycle, so outbreaks continue to occur globally. Given the degree of concern expressed by physicians, a rational, evidence-based approach to case management that moves beyond passive symptom management and toward active viral mitigation and immune support would seem to be in order.

Decades of research have underscored the importance of nutritional, immune-modulating, and antiviral interventions, yet no standardized clinical protocol has emerged. Given the cumulative evidence from studies spanning 1948 to 2025, this article proposes a structured, tiered approach to measles management and calls for targeted clinical trials to validate an optimal protocol.

The Proposed Measles Management Protocol

The first step in managing measles is supporting the immune system and mitigating complications. Most fatalities occur not from the virus itself but from secondary infections, vitamin deficiencies, and immune suppression.

I. Routine Care: Early-Stage & Uncomplicated Cases

• High-Dose Vitamin A (Retinol)

  • Evidence: Clinical trials have demonstrated that two high doses of vitamin A significantly reduce measles mortality and morbidity in children, especially those with malnutrition or complications like pneumonia​.

  • Proposed Dosage: WHO-recommended regimen—200,000 IU for children ≥12 months; 100,000 IU for infants <12 months—on consecutive days.

• Vitamin C (Ascorbic Acid)

  • Evidence: High-dose vitamin C has been documented to reduce viral load, improve immune function, and mitigate oxidative stress in viral infections, though controlled trials in measles are lacking​.

  • Proposed Dosage: 3-5g daily (oral liposomal or IV for severe cases); higher doses could be explored based on bowel tolerance.

• Vitamin D3 (Cholecalciferol)

  • Evidence: Vitamin D is a critical regulator of immune function, with well-documented antiviral, anti-inflammatory, and immune-modulating properties. Studies have shown that vitamin D enhances innate immune responses by promoting the production of antimicrobial peptides (cathelicidin and defensins), which can reduce viral replication. It also modulates cytokine responses, helping to prevent excessive inflammation and cytokine storm events seen in severe viral infections. While direct studies on vitamin D in measles management are limited, evidence from respiratory infections, tuberculosis, and other viral diseases suggests that adequate vitamin D levels correlate with better outcomes.

  • Proposed Dosage:

    • Routine cases: 5,000–10,000 IU daily (oral) for adults; 2,000–5,000 IU for children, with appropriate serum 25(OH)D levels monitoring.

    • Progressing cases: 50,000 IU once weekly for 4 weeks to rapidly restore serum levels, then transition to daily maintenance dosing.

    • Severe cases: Single high-dose bolus of 100,000 IU, followed by daily 10,000 IU maintenance to support immune response and prevent acute deficiency-related complications.

• Iodine Supplementation

  • Evidence: Iodine plays a critical role in immune function and mucosal barrier integrity, which are compromised in measles. Nebulized or oral iodine has been used in viral infections to reduce viral load​.

  • Proposed Dosage: Lugol’s iodine 1-2 drops daily in water, nebulized iodine in progressive cases.

• Lysine & N-Acetylcysteine (NAC)

  • Evidence: Lysine has demonstrated antiviral properties, particularly in herpesvirus infections, and may modulate immune response in measles. NAC is a potent antioxidant that reduces lung inflammation and supports glutathione synthesis, a key factor in immune resilience​.

  • Proposed Dosage:

    • Lysine: 1-2g daily.

    • NAC: 600mg 1-2x daily.

• Gut Microbiome Support: Pre- and Probiotics

  • Evidence: The gut microbiome plays a major role in immune regulation, and measles virus significantly depletes beneficial gut flora, leading to prolonged immune suppression and vulnerability to secondary infections​.

  • Proposed Regimen: Broad-spectrum probiotic with Lactobacillus and Bifidobacterium strains; prebiotic fiber (inulin, FOS).

• Epsom Salt Baths with Hydrogen Peroxide, Followed by Organic Oatmeal Milk Baths

  • Evidence: Magnesium sulfate (Epsom salt) supports detoxification pathways and soothes neurological symptoms. Hydrogen peroxide may aid in viral clearance via oxidative stress modulation, while organic oatmeal milk baths reduce skin inflammation and discomfort​.

  • Proposed Protocol:

    • Epsom salt bath (2 cups) + hydrogen peroxide (1 cup): 20-minute soak.

    • Followed by organic oatmeal-milk bath for skin barrier support.

---

II. Progressing Cases: When Routine Care Isn’t Enough

In cases where symptoms worsen or complications arise, additional therapies are warranted to reduce viral load, mitigate inflammation, and restore immune homeostasis.

1. Ozone Therapy

   • Evidence: Ozone therapy has potent antiviral, oxygenation, and immune-modulating effects. It has been used successfully in viral infections, including measles-like paramyxoviruses​.

   • Proposed Methods:

     • Rectal Insufflation: Daily low-dose ozone therapy (200-400cc at 20-30 gamma).

     • Ozonated Saline IV for severe cases.

2. Intravenous Glutathione

   • Evidence: Measles infection depletes glutathione, the body’s master antioxidant, exacerbating oxidative stress and immune suppression. IV glutathione has been shown to reduce complications in viral infections​.

   • Proposed Dosage: 600-1200mg IV daily.

3. High-Dose Intravenous Vitamin C

   • Evidence: IV vitamin C can act as a potent antiviral, reducing inflammation and supporting immune resilience in severe viral infections​.

   • Proposed Dosage: 10-25g IV daily until resolution of symptoms.

---

III. Severe Cases: Last-Resort Interventions

If life-threatening complications develop, such as encephalitis, respiratory failure, or organ failure, more aggressive interventions should be deployed.

1. Plasma Exchange (Therapeutic Plasma Apheresis)

   • Evidence: Plasma exchange has been used in severe viral encephalitis and immune dysregulation disorders, suggesting potential benefit in measles-induced cytokine storms​.

   • Proposed Use: Considered in encephalitis, acute respiratory distress syndrome (ARDS), or severe systemic inflammation.

2. Restarting the Routine Care Protocol

   • Following plasma exchange, the patient should restart at the routine care level, with continued IV glutathione, vitamin C, and ozone therapy as needed.

---

Call for Research: Evaluating This Protocol

While elements of this protocol are supported by decades of research, no cohesive clinical framework has been implemented. We propose urgent research to evaluate the efficacy of these interventions in measles cases, particularly in high-risk populations.

Specific Research Priorities

1. Clinical Trials on High-Dose Vitamin A, Vitamin D, Vitamin C and Glutathione in Measles

2. Ozone Therapy’s Role in Viral Clearance and Immune Modulation

3. Plasma Exchange for Severe Measles-Associated Encephalitis

4. Comprehensive Nutritional & Microbiome Interventions for Immune Recovery

5. Comparative Outcomes of Patients Receiving IV Therapies vs. Standard Supportive Care

IP2H Approach: Proposed Research Studies on Combined Measles Therapies

To establish an optimal evidence-based measles treatment protocol, comparative studies should investigate synergistic effects of multiple therapies rather than testing isolated interventions. Below are three proposed study arms for a clinical trial evaluating combinations of therapies that address immune support, viral mitigation, and complication reduction.

---

Establishing an Evidence-Based Measles Management Protocol

The primary goal of this research initiative is to move beyond passive symptom management and assess the efficacy of combined treatment approaches that support immune resilience, mitigate viral load, and reduce long-term complications.

Given the immunological variability across different populations, the proposed studies will evaluate targeted interventions across key high-risk groups, including infants, children, pregnant women, elderly patients, and those with immune suppression. The research is structured to test combinations of therapies in progressive stages of disease, focusing on routine supportive care, advancing to intravenous and oxidative therapies for worsening cases, and ultimately testing advanced interventions such as plasma exchange in severe cases. The objective is to determine which treatment combinations are most effective at reducing morbidity and mortality while ensuring safety and feasibility in clinical practice.

---

Study 1: Oral Glutathione Precursors vs. L-Lysine in Measles Recovery

This randomized controlled trial will compare the effectiveness of oral glutathione precursors (L-cystine, NAC, and glycine) versus L-lysine in reducing measles severity, improving immune function, and mitigating oxidative stress. The trial will include infants aged 3-12 months, children 1-12 years with a high risk of complications, and elderly patients over 60 years with underlying inflammatory conditions or comorbidities.

Patients should be randomized into three treatment groups. The first group will receive a combination of L-cystine (500-1000mg/day), NAC (300-600mg/day), and glycine (1-2g/day) alongside standard care, which includes vitamin A, vitamin C, probiotic support, and hydration therapy. The second group will receive L-lysine (1-2g/day) in place of L-cystine, with otherwise identical support. The third group will serve as the control, receiving standard supportive care without additional amino acid supplementation.

Outcomes and Monitoring

The primary outcomes of this study will include the time to resolution of fever and rash, incidence of secondary infections such as pneumonia and otitis media, hospitalization rates, and duration of symptoms. Biomarker analysis will assess glutathione levels, oxidative stress markers, immune cell function, and inflammatory cytokines to determine whether either intervention provides measurable biochemical benefits.

To ensure patient safety, the study will include frequent metabolic monitoring to prevent excessive amino acid accumulation, particularly in infants. All parents or guardians will provide informed consent, and elderly participants will undergo cognitive assessments to confirm their ability to provide consent independently. Any participants exhibiting unexpected worsening of symptoms or adverse metabolic effects should be withdrawn from the study.

---

Study 2: IV Therapies vs. Ozone Therapy in Progressing Cases

For patients in whom measles progresses beyond routine care into moderate or severe illness, this study should evaluate the effectiveness of intravenous glutathione and vitamin C versus ozone therapy. Participants will include children between 1 and 12 years experiencing prolonged fever, respiratory distress, or gastrointestinal complications, elderly patients with increasing inflammatory markers, and pregnant women diagnosed with measles pneumonia.

Patients should be assigned to one of three treatment groups. The first will receive IV glutathione (1.2g/day) and IV vitamin C (15-25g/day), administered to counteract oxidative stress and support immune function. The second group will receive rectal ozone therapy (200cc at 20-30 gamma daily) alongside ozonated saline IV therapy (twice per week). The third group will serve as the control, receiving high-dose oral vitamin C (up to 5g/day), vitamin A supplementation, probiotic therapy, and hydration support.

Outcomes and Monitoring

Primary outcomes will focus on the progression of illness, including rates of severe pneumonia, encephalitis, and acute respiratory distress syndrome (ARDS). Laboratory monitoring will assess inflammatory markers (IL-6, TNF-alpha, and CRP), immune response (T-cell function), and viral clearance rates. Hospitalization duration and survival rates will also be recorded.

Safety concerns related to ozone therapy should be addressed through pre-screening for contraindications such as G6PD deficiency, pregnancy restrictions, and chronic inflammatory disorders that could exacerbate oxidative stress. Immunocompromised patients will undergo more frequent metabolic screening to ensure proper detoxification pathways remain intact. Pregnant women should be monitored with continuous fetal assessments to ensure no negative effects from either therapy.

---

Study 3: Plasma Exchange vs. High-Dose IV Therapies in Severe Cases

Severe cases of measles—particularly those presenting with encephalitis, ARDS, or cytokine storm—may require more aggressive interventions. This study will compare therapeutic plasma exchange (TPE) with high-dose IV glutathione, vitamin C, and methylene blue therapy. Participants will include children with SSPE risk, elderly patients experiencing respiratory failure, and critically ill individuals admitted to intensive care units.

Patients in the first treatment group will undergo low-volume plasma exchange sessions designed to remove immune complexes and inflammatory cytokines while minimizing hemodynamic instability. The second group will receive IV glutathione (1.5g), high-dose IV vitamin C (50g), and IV methylene blue (1mg/kg) to address neuroinflammation, oxidative stress, and mitochondrial dysfunction. A combined therapy group will allow the study of interaction between the two treatment types. The control group will receive standard ICU care, including high-dose IV vitamin C alone.

Outcomes and Monitoring

The study will evaluate mortality rates, neurological function recovery, pulmonary function post-ARDS, and inflammatory cytokine reduction. EEG studies and cognitive function tests should be performed to assess neurological recovery in encephalitic patients. Lung function tests will determine whether these therapies improve oxygenation and reduce lung inflammation in severe pneumonia cases.

To mitigate risks, strict patient selection criteria should be enforced for plasma exchange, ensuring frail elderly or neonates with unstable blood pressure are excluded. ICU patients receiving methylene blue should be carefully monitored due to potential methemoglobinemia risks. Ethical oversight committees will review each case before inclusion in the study.

---

Ensuring IRB Compliance & Ethical Considerations

This research framework has been designed to fully address ethical, safety, and regulatory considerations. All interventions, including those considered experimental, are justified by prior evidence in related conditions and should be monitored under strict safety protocols.

Each trial includes adaptive stopping criteria, ensuring that any participant exhibiting adverse reactions or worsening clinical status is removed from the study immediately. Parental consent for infants, cognitive screening for elderly participants, and pregnancy-specific safety protocols should be rigorously enforced.

In terms of regulatory compliance, this research follows Good Clinical Practice (GCP) guidelines and should be registered with ClinicalTrials.gov for transparency. Ethical approvals should be sought from multiple independent review boards to ensure that high-risk groups are protected under the most stringent ethical standards.

---

Conclusion & Research Impact

This research aims to provide high-quality, comparative data to develop a rational, evidence-based measles treatment protocol that goes beyond symptom management. By evaluating synergistic therapies across disease progression stages, this study has the potential to revolutionize the clinical management of measles, reduce mortality rates, and improve post-viral immune recovery.

With a focus on nutritional, immune-modulating, and oxidative stress-targeted therapies, this protocol represents the type of step forward in measles treatment innovation that should calm the nerves of anxious physicians.